Ceragenix Pharmaceuticals, Inc. Release: Japanese Researchers Find CSA-13 May Be Useful for Prevention and Treatment of Dental Caries and Periodontal Disease
DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the "Company"), a medical device company focused on infectious disease and dermatology, today announced that in vitro research conducted at the Health Sciences University of Hokkaido (Hokkaido, Japan) found that CSA-13, the Company’s lead Ceragenin™ class of antimicrobial compound, had potent bactericidal activity against all 23 strains of oral bacteria related to dental caries and periodontal disease including protease positive strains. The strains tested were isolates of Streptococccus mutans and Poryphyromonas species. The lead investigator was Dr. Emiko Isogai, a Professor at the Department of Disease Control and Molecular Epidemiology. Findings from the testing were published in the February issue of Oral Microbiology and Immunology.